BioMedNewsBreaks — $ANVS Expands Team in Continued Focus to Make Meaningful Impact on Lives of AD, PD Patients https://ibn.fm/HxM26
BioMedWire
Online Audio and Video Media
San Francisco, California 3,794 followers
Keeping the public abreast of the latest developments related to emerging market opportunities in the sector.
About us
A specialized communications platform, a digital hub that aggregates and distributes news and information on the latest developments in the life sciences sector. Designed to quickly update investors on important industry news, BioMedWire is committed to keeping the public abreast of the latest developments related to emerging market opportunities in the sector. We cover companies and events in the fields of biotechnology, pharmaceuticals, life systems technologies, environmental, nutraceuticals, cosmeceuticals, medical, biomedical devices and more. We delve into people, companies and institutions that are devoted to the research and development of the next cancer therapeutic, critical device or lifesaving vaccine. BioMedWire has established a reputation as the go to source for its coverage of sector events that have market moving impact. Some of the greatest market returns have been delivered by the life sciences which has provided cures and remedies for the masses and massive rewards for investors. As a champion of the life sciences, BMW is committed to connecting the investing public to the intelligence used to identify the sector’s next great success story. The life sciences, pharmaceutical and biotech industries are massive and move quickly, BMW strives to provide the most comprehensive industry news and information to keep followers and investors up to date on important developments. From mergers to drug and device approvals, the business is constantly changing, and we’ll do our best to keep you abreast of what matters. BioMedWire provides insights into the most impactful news and trends shaping the life sciences sector and beyond. We endeavor to shed new light on companies in the sector with breakout potential, ready to market a new therapy or device, on their way to becoming industry heavyweights. Follow us to find the insights and the opportunities in the sector that has the greatest impact on humanity's well-being. Disclaimer: http://ibn.fm/bmw
- Website
-
https://www.biomedwire.com
External link for BioMedWire
- Industry
- Online Audio and Video Media
- Company size
- 1 employee
- Headquarters
- San Francisco, California
- Type
- Privately Held
Locations
-
Primary
Get directions
San Francisco, California, US
Employees at BioMedWire
Updates
-
BioMedNewsBreaks — $CLNN Positioned as Leader in Addressing Neurodegenerative Diseases https://ibn.fm/0Ug43
-
-
$AZN is boosting its commitment with an additional $135 million investment in its Swedish biologics facility, further strengthening its R&D capabilities. This expansion aims to accelerate the development of innovative therapies: https://ibn.fm/wEsRj #AstraZeneca #Biologics
-
$MRK is discontinuing the KEYNOTE-867 and KEYNOTE-630 trials of pembrolizumab in NSCLC and CSCC. This decision reflects ongoing adjustments in clinical research strategies: https://ibn.fm/GsGBV #Merck #ImmunoOncology #ClinicalTrials #NSCLC #CSCC
Merck to Discontinue KEYNOTE-867 and KEYNOTE-630 Trials of Pembrolizumab in NSCLC, CSCC
onclive.com
-
$J&J Rybrevant, in combination with chemotherapy, has been approved by the EC for expanded use in treating lung cancer. This approval marks a significant advancement in targeted cancer therapy for patients in Europe: https://ibn.fm/ZdPWN #LungCancer #CancerTreatment
Johnson & Johnson's Rybrevant combination approved by EC for expanded lung cancer use - PMLiVE
https://pmlive.com
-
$MRK Phase 3 KEYNOTE-A39/AEGEAN trial shows significant improvement in event-free survival for resectable non-small cell lung cancer. A step forward in cancer treatment: https://ibn.fm/koeZS #Merck #LungCancer #KEYTRUDA #Pharma #ClinicalTrials
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
finance.yahoo.com
-
$CLNN CEO Discusses Company’s Mission, CNM-Au8(R) Trial Results, and Future Plans on BioMedWire Podcast https://ibn.fm/Bmgzn
-
-
$AZN is boosting its biologics production capacity in Sweden with a major investment. This expansion will enhance their ability to deliver innovative treatments: https://ibn.fm/MXuHQ #AstraZeneca #Biologics #Pharmaceuticals #Innovation #Healthcare
AstraZeneca investment to increase biologic capacity in Sweden
https://www.europeanpharmaceuticalreview.com
-
Proposed US Law Would Direct Opioid Settlement Cash to Opioid Crisis Management $NTRB https://ibn.fm/1owHd #biomedstocks #opioids
-
-
$MRK has won EC approval for Winrevair, enhancing respiratory treatment options in Europe. This marks another step forward in healthcare innovation: https://ibn.fm/MWtj9 #Merck #Winrevair #RespiratoryHealth #Pharma #Healthcare
Merck wins EC approval for Winrevair